FY26 EPS > INR 100
Management stated MPS is comfortably placed to surpass INR 100 EPS in FY26, describing it as a conservative target. Note: Q3 labor code impact creates ~3.5 rupee headwind per share, and Q4 is expected to outperform Q3 benchmarks.
MPSLTD / guidance tracker
Keep management guidance in view.
MPS · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
AJ Stable Revenue in FY27
Research Solutions AJ business expected to show stable revenue in FY27 with new B2B publisher partnerships, editorial services expansion, and competitive pricing improvements on B2C services driving order value recovery.
Corporate Learning Return to Growth in FY27
Corporate Learning segment expected to return to growth in FY27 following Q3 restructuring, cost optimization, pivot to managed learning services, and AI-enabled solutions focus.
Unbound Acquisition Closing
Unbound Medicine acquisition expected to close by February 10, 2026 for $16.5M. Revenue will be classified primarily under Education segment with some Research; B2B subscription model with high recurring revenue and institutional stickiness.